IDH2 and cancer: In these cancers, IDH1 and IDH2 variants are thought to alter the catalytic function of the mutant enzymes, leading to the production of the oncometabolite D-2-hydroxyglutarate (D-2HG) from α-ketoglutarate (α-KG)[9].